National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Salivary Gland Cancer Treatment (PDQ®)
Patient VersionHealth Professional VersionEn españolLast Modified: 05/08/2008



Purpose of This PDQ Summary






General Information






Cellular Classification






Stage Information






Treatment Option Overview






Stage I Major Salivary Gland Cancer






Stage II Major Salivary Gland Cancer






Stage III Major Salivary Gland Cancer






Stage IV Major Salivary Gland Cancer







Recurrent Major Salivary Gland Cancer






Get More Information From NCI






Changes to This Summary (05/08/2008)






More Information



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
New Study of Targeted Therapies for Breast Cancer

The Nation's Investment in Cancer Research FY 2009

President's Cancer Panel Annual Report: 2006-2007

Cancer Trends Progress Report: 2007 Update

Past Highlights
HPV Vaccines for Cervical Cancer
Recurrent Major Salivary Gland Cancer

Current Clinical Trials

The prognosis for any treated cancer patient with progressing or relapsing disease is poor, regardless of cell type or stage. Selecting further treatment depends on many factors, including the specific cancer, prior treatment, site of recurrence, and individual patient considerations. Fast neutron-radiation therapy is superior to conventional radiation therapy using x-rays and may be curative in selected cases of recurrent disease.[1]

Disease-free and overall survival for patients with inoperable, unresectable, or recurrent malignant salivary gland tumors is superior in patients treated with fast neutron radiation as compared to those treated with conventional x-ray radiation therapy.[2-5] Clinical trials are appropriate and should be considered when possible.

Current Clinical Trials

Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with recurrent salivary gland cancer. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.

General information about clinical trials is also available from the NCI Web site.

References

  1. Laramore GE, Krall JM, Griffin TW, et al.: Neutron versus photon irradiation for unresectable salivary gland tumors: final report of an RTOG-MRC randomized clinical trial. Radiation Therapy Oncology Group. Medical Research Council. Int J Radiat Oncol Biol Phys 27 (2): 235-40, 1993.  [PUBMED Abstract]

  2. Laramore GE: Fast neutron radiotherapy for inoperable salivary gland tumors: is it the treatment of choice? Int J Radiat Oncol Biol Phys 13 (9): 1421-3, 1987.  [PUBMED Abstract]

  3. Saroja KR, Mansell J, Hendrickson FR, et al.: An update on malignant salivary gland tumors treated with neutrons at Fermilab. Int J Radiat Oncol Biol Phys 13 (9): 1319-25, 1987.  [PUBMED Abstract]

  4. Buchholz TA, Laramore GE, Griffin BR, et al.: The role of fast neutron radiation therapy in the management of advanced salivary gland malignant neoplasms. Cancer 69 (11): 2779-88, 1992.  [PUBMED Abstract]

  5. Krüll A, Schwarz R, Engenhart R, et al.: European results in neutron therapy of malignant salivary gland tumors. Bull Cancer Radiother 83 (Suppl): 125-9s, 1996.  [PUBMED Abstract]

Back to TopBack to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov